This Week’s Biotech, Nanotech and Mining Stocks also
added to Investor Directories
Point Roberts, WA, Delta BC – February 24, 2017 –
Investorideas.com, a global news source and investor resource covering actively
traded sectors announces this week’s additions to its investor membership, including global stock directories in biotech, nanotech and mining
Investorideas.com tracks companies in high profile
trading sectors and makes ongoing additions to its stock directories for each
sector. Listing for the stock directories include companies on the
TSX, OTC, NYSE, NASDAQ and global stock exchanges.
The latest Biotech companies include those working
with cannabinoids along with companies working in pain management, oncology,
weight management, cystic fibrosis, OTC Medications, treatment for neurological
diseases such as Alzheimer’s and ALS, kidney and vascular disease and new oral
drug delivery systems.
Nanotech company additions coincide with a fully
updated Nanotechnology stock list and include a cross-over company into the
biotech sector, a company that provides nanotech tools and an investment
company that has formed a joint partnership with Vietnam-based Nanotech firm.
New mining companies are both operating in Canada
(Ontario and Quebec) and mining for copper and gold respectively.
New Biotech Companies Added:
Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA) a
biopharmaceutical company, discovers, develops, and commercializes novel drugs
that target G protein-coupled receptors. The company offers BELVIQ, a drug used
to treat chronic weight management in adults. One of the products under
development is APD371, an agonist of the cannabinoid receptor 2 that is in
Phase I single-ascending dose trial for the treatment of pain. The company also
manufactures drug products under a manufacturing services agreement for
Siegfried AG
Cara Therapeutics, Inc. (NasdaqGM:CARA) is a clinical-stage biotechnology company focused on
developing and commercializing new chemical entities designed to alleviate pain
and pruritus by selectively targeting peripheral kappa opioid receptors. Cara
is developing a novel and proprietary class of product candidates that target
the body's peripheral nervous system and have demonstrated initial efficacy in
patients with moderate-to-severe pain without inducing many of the undesirable
side effects typically associated with currently available pain therapeutics.
Cerulean Pharma Inc. (NasdaqGM:CERU) The Cerulean team is
committed to improving treatment for people living with cancer. We apply our
Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug
conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity
by sparing the body's normal cells, and enable therapeutic combinations. Our
first platform-generated NDC clinical candidate, CRLX101, is in clinical trials
in combination with other cancer treatments, all of which aim to unlock the
power of combination therapy. Our second platform-generated NDC clinical
candidate, CRLX301, is in a Phase 1/2a clinical trial.
Corbus Pharmaceuticals Holdings, Inc. (NasdaqGM:CRBP) is a clinical
stage pharmaceutical company focused on the development and commercialization
of novel therapeutics to treat rare, chronic, and serious inflammatory and
fibrotic diseases. The Company's lead product candidate, JBT- 101, is a novel
synthetic oral endocannabinoid-mimetic drug designed to resolve chronic
inflammation, and fibrotic processes. In November 2016, Corbus reported
positive topline data results from a Phase 2 study in diffuse cutaneous
systemic sclerosis, showing clear signal of clinical benefit with JBT-101. The
Company recently completed a Phase 2 study of JBT-101 for the treatment of
cystic fibrosis with topline data expected to be announced before the end of the
first quarter of 2017. Additionally, JBT-101 is being evaluated in a Phase 2,
12-month open label extension study in systemic sclerosis, a Phase 2 study in
skin-predominant dermatomyositis, with a 12-month open label extension study in
dermatomyositis and another Phase 2 study in systemic lupus erythematosus
planned to commence in the first quarter of 2017.
CTT Pharmaceutical Holdings Inc. (OTCQB:CTTH) principal
asset is a unique and novel patented drug delivery technology, an orally
administered, fast dissolving thin film (the "Wafer"). This
technology platform will target both the human and veterinarian (pet) markets
for treatment of many diseases including pain management. The Oral Thin Film
(Wafer) formulation is protected by several Canadian and US Patents. CTT's oral
fast dissolving drug delivery systems will consist of edible thin films
(wafers) that dissolve without water, within a few seconds after placement in
the mouth. The majority of drugs administered using our drug delivery system
mirror injections in that they have the ability to enter the bloodstream
quickly, are convenient and discrete, and can be administered anywhere. A
faster absorption rate is achieved because the mouth contains a very thin
mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation
as is the case with cannabis, and less degradation of medication (by bypassing
the stomach) and most importantly lower dosage units are required given the
efficacy of absorption. Patient compliance is improved, especially with those
who have a fear of choking and/or are pediatric, geriatric or incapacitated
patients who have difficulty swallowing. Most fast dissolving systems on the
market today deliver anti-inflammatories, antihistamines and cough and
breathing related medications. CTT believes that its Wafer technology will be
one of the first to gain use in major markets such as pain management.
Innovus Pharmaceuticals, Inc. (OTC: INNV) is an emerging over-the-counter (“OTC”) consumer goods and
specialty pharmaceutical company engaged in the commercialization, licensing
and development of safe and effective non-prescription medicine and consumer
care products to improve men’s and women’s health and vitality and respiratory
diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and health
products, which we market directly, (b) commercial partners to primary care
physicians, urologists, gynecologists and therapists, and (c) directly to
consumers through our on-line channels, retailers and wholesalers. The Company
is dedicated to being a leader in developing and marketing new OTC and branded
Abbreviated New Drug Application (“ANDA”) products. The Company is actively
pursuing opportunities where existing prescription drugs have recently, or are
expected to, change from prescription (or Rx) to OTC.
Mateon
Therapeutics, Inc. (NasdaqCM: MATN) is a
biopharmaceutical company seeking to realize the full potential of vascular
targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents
(VDAs) such as the investigational drugs that Mateon is developing, and
anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used
in cancer treatment. These two approaches have distinct yet complementary
mechanisms of action. At Mateon, we believe that we can significantly improve
cancer therapy by employing these two complementary approaches simultaneously.
When utilized this way, VDAs obstruct existing blood vessels in the tumor
leading to significant central tumor cell death while AAs prevent the formation
of new tumor blood vessels. Mateon is committed to leveraging our intellectual
property and the product development expertise of our highly skilled management
team to enable VTT to realize its true potential and to bring much-needed new
therapies to cancer patients worldwide.
Mirna
Therapeutics, Inc. (NasdaqGM: MIRN) is
a clinical stage biopharmaceutical company developing a pipeline of
microRNA-based oncology therapeutics and is the first to bring a synthetic
microRNA mimic into clinical development for the treatment of cancer. Mirna's
lead product candidate, MRX34, a mimic of naturally occurring microRNA-34
(miR-34), is being studied in a Phase 1 clinical trial which has included
patients with primary liver cancer, advanced solid tumors and hematological
malignancies. miR-34 is one of the most widely published microRNAs and is
considered a key regulator of multiple oncogenes across key oncogenic pathways,
with the capacity to regulate more than 30 different oncogenes and repress
immune checkpoint signaling molecules, including PD-L1. The potential capacity
to simultaneously affect multiple pathways and processes that are critical to
cancer cell viability may make mimics of tumor suppressor microRNAs an
important new class of anti-cancer agents. Mirna plans to develop MRX34 as a monotherapy
and in combination with other therapies. The Company was founded in 2007 and is
located in Austin, Texas.
Nivalis
Therapeutics, Inc. (NasdaqGM: NVLS) is
a pharmaceutical company that has historically been focused on the discovery
and development of product candidates for patients with cystic fibrosis, or CF.
Our GSNOR inhibitors selectively target an enzyme known as S-nitrosoglutathione
reductase, which we refer to as GSNOR. GSNOR regulates levels of an endogenous
protein known as S-nitrosoglutathione, or GSNO.
Depleted levels of GSNO have been associated with CF, asthma,
inflammatory bowel diseases and certain cardiovascular diseases. However, in
light of recent disappointing results of a Phase 2 clinical trial of our lead
product candidate, cavosonstat, in CF, we determined to not pursue the
development of this compound in CF and to wind down our research and
development activities as we shift our strategic emphasis to investigating and
evaluating strategic alternatives.
Oramed
Pharmaceuticals Inc. (NasdaqCM: ORMP) is
a platform technology pioneer in the field of oral delivery solutions for drugs
currently delivered via injection. Established in 2006, Oramed's Protein Oral
Delivery (PODTM) technology is based on over 30 years of research by scientists
at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the
treatment of diabetes through its proprietary flagship product, an orally
ingestible insulin capsule (ORMD-0801).
The Company completed multiple Phase II clinical trials of ORMD-0801
under an Investigational New Drug application with the U.S. Food and Drug
Administration. In addition, Oramed is developing an oral GLP-1 analog capsule
(ORMD-0901).
ProMIS Neurosciences Inc. (TSX: PMN.TO) The mission of ProMIS Neurosciences is to
discover and develop precision medicine therapeutics for effective treatment of
neurodegenerative diseases, in particular Alzheimer's disease and ALS. ProMIS
Neurosciences' proprietary target discovery engine is based on the use of two,
complementary techniques. The Company applies its thermodynamic, computational
discovery platform—ProMIS™ and Collective Coordinates — to predict novel
targets known as Disease Specific Epitopes (DSEs) on the molecular surface of
misfolded proteins. Using this unique "precision medicine" approach,
ProMIS Neurosciences is developing novel antibody therapeutics and specific
companion diagnostics for Alzheimer's disease and ALS. The company has also
developed two proprietary technologies to specifically identify very low levels
of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences
owns a portfolio of therapeutic and diagnostic patents relating to misfolded
SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic
against this target.
Proteon Therapeutics Inc. (NasdaqGM: PRTO) is
committed to improving the health of patients with kidney and vascular diseases
through the development of novel, first-in-class therapeutics. Proteon's lead
product candidate, vonapanitase, is an investigational drug intended to improve
hemodialysis vascular access outcomes. Proteon is currently enrolling patients
in a Phase 3 clinical trial, PATENCY-2. Proteon is also evaluating vonapanitase
in Phase 1 clinical trials in patients with peripheral artery disease (PAD).
New Nanotech Companies Added:
Cerulean Pharma Inc. (NasdaqGM:CERU) The Cerulean team is
committed to improving treatment for people living with cancer. We apply our
Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug
conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity
by sparing the body's normal cells, and enable therapeutic combinations. Our
first platform-generated NDC clinical candidate, CRLX101, is in clinical trials
in combination with other cancer treatments, all of which aim to unlock the
power of combination therapy. Our second platform-generated NDC clinical
candidate, CRLX301, is in a Phase 1/2a clinical trial.
Oxford Instruments PLC (LSE:OXIG.L) is a provider of technology tools and systems for
industry and research. The Company operates through three segments:
Nanotechnology Tools, Industrial Products and Service. The Nanotechnology Tools
segment offers technology products serving research customers in both the
public and private sectors. The Industrial Products segment contains a group of
businesses supplying technology products and components manufactured in medium
volume for industrial customers. The Service segment contains the Company's
service, rental and refurbished asset sales business. Its NanoAnalysis business
delivers solutions and services that enable materials characterization and
sample manipulation at the nano scale. Its products are used on electron
microscopes and ion-beam systems in academic institutions and industrial
applications, including semi-conductors, renewable energy, mining, metallurgy
and forensics. Its products include AZtecOne and X-Max Extreme detector, among
others.
PHI Group Inc. (OTC:PHIL) primarily focuses on acquisitions as a principal
and invests in energy, natural resources and special situations that may
substantially enhance shareholder value.
In addition, the Company also provides merger and acquisition advisory
services through its wholly owned subsidiary PHI Capital Holdings, Inc. and earns revenues in forms
of cash and equity for services rendered. Nanotech – January 2017: signed an
agreement with Nhat Hai New Technology JSC, a Vietnam-based company
specializing in applied research and nanotechnologies
(http://www.nanotechnology.com.vn), to form a joint venture company in the
United States to apply the latter’s nanotechnologies for the production of
various nano products.
New Mining Companies Added:
Hadley Mining Inc. (CSE:HM)
is a Toronto based mineral company which owns 25% of the Pigeon River
nickel-copper claim in Ontario.
Secova Metals Corp (TSX:SEK.V; OTC:SEKZF; Frankfurt: N4UN.F) is a Canadian gold exploration company
focused on building a strong asset base through exploration of undervalued gold
projects in Canada. Management has demonstrated expertise in advancing gold
exploration projects into acquisition targets, most notably in the province of
Quebec. Secova has the exclusive right and option to acquire from Tres-Or
Resources Inc. ("Tres-Or"), an undivided 65% right, title and
interest in the contiguous Duvay and Chenier Gold Projects. Secova can earn up
to 90% of the property (an additional 25% ownership) by funding a
pre-feasibility study after the initial exploration expenditures to bring the
property towards production. The Company has a total contiguous land package of
174 claims covering over 7,766 hectares (17,458 acres) of land. Duvay/Chenier
is located in the Abitibi gold belt, one of Quebec's premier mining
jurisdictions. The Company has plans to advance the development of
Duvay/Chenier as well as seek other avenues of growth through acquisition and
mergers. The Company also has 100% ownership of the Eagle River project which
is adjacent to and on-trend to several gold projects in the Windfall Lake
district of Urban Barry in Quebec. The Company wholly owns the Cobalt Bay
property which is 1,996 hectares and just 102kms north of its Eagle River
project in Quebec.
Investorideas.com
global stock directories are part of the membership program on the site,
accessed either by login and password or available in PDF format. The
directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other
recognized global stock exchanges, giving retail investors a wide variety of
stocks to review. http://www.investorideas.com/membership/
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
About
Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a
meeting place for global investors, featuring news, stock directories, video,
company profiles, interviews and more in leading sectors.
Sectors we cover include
tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water
stocks, marijuana and hemp stocks, food and beverage (including organic and
LOHAS, wine), defense and security (including biometrics), Latin America,
sports, entertainment, luxury brands and gaming.
The Investorideas.com content portfolio goes beyond
the www.investorideas.com site to include 12
blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid
and the Waternewswire.com, all featuring Investorideas.com news and content.
Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks,
renewable energy, nanotech, defense, technology, biotech and more – use our
stock directories and access them online 24/7 with login as a member to find
your next big idea!
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution,social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.
Contact Investorideas.com
800-665-0411
